A daily dose of antiretroviral medications is lifesaving for HIV-positive individuals. It’s the key to achieving full viral suppression that will lead to a long and productive existence. Regimen adherence issues, however, are very common among certain groups. Injectable antiretrovirals are proving to be a good choice for such patients who experience difficulties sticking to ART.

Finding a cure for HIV is currently impossible because of the hidden DNA “reservoirs” the virus creates inside the human body. New gene editing experiments suggest that the technology could be used to target these reservoirs, thus helping for the development of an effective HIV treatment.

A new report suggests that antiretroviral therapy has been made available to 90 per cent of HIV-positive individuals in China. Of these people, 90 per cent have achieved undetectable viral load. The numbers demonstrate just how effective a nation-wide treatment and healthcare programme can be.

Daily HIV PrEP in the form of a pill is a readily available, highly effective prevention option. Newer choices are becoming available but research suggests that users are still most drawn to using the daily dose medication.

HIV self-testing kits have been making headlines lately because they empower individuals and supposedly make testing more accessible. Is this really so? Statistics suggest that the effectiveness of this prevention approach may not be as high as originally anticipated.

PrEP use during pregnancy hasn’t been studied so far. A new study provides insightful information about the safety of antiretroviral medications used to diminish the risk of contracting HIV in the event of exposure. Researchers found out that PrEP use during pregnancy is not linked to adverse outcomes.

HIV-positive individuals have to take their daily dose of antiretroviral medications to suppress the virus and keep it from replicating. Researchers are now experimenting with a new gel-like formula that will completely eliminate the need for taking a daily dose.

PrEP use during pregnancy hasn’t been studied so far. A new study provides insightful information about the safety of antiretroviral medications used to diminish the risk of contracting HIV in the event of exposure. Researchers found out that PrEP use during pregnancy is not linked to adverse outcomes.